Latent viral infections in young patients with inflammatory diseases treated with biological agents: Prevalence of JC virus genotype 2

Journal of Medical Virology

Volumn 85, Issue 4, 2013, Pages 716-722

  Comar, Manola ^a,b   Delbue, Serena ^c   Lepore, Loredana ^b   Martelossi, Stefano ^b   Radillo, Oriano ^b   Ronfani, Luca ^b   D'Agaro, Pierlanfranco ^a,b   Ferrante, Pasquale ^d,e  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c Health Science Foundation Ettore Sansavini   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Città Studi Clinical Institute   (Italy)

Author keywords

Children; Human herpesviruses; Inflammatory bowel diseases; Infliximab; JC virus

Indexed keywords

ETANERCEPT; INFLIXIMAB;

ADOLESCENT; ARTICLE; BLOOD ANALYSIS; CHILD; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; EPSTEIN BARR VIRUS; FEMALE; GENE SEQUENCE; GENOTYPE; HERPES VIRUS INFECTION; HUMAN; IMMUNOTHERAPY; JC VIRUS; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PEDIATRICS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYOMAVIRUS INFECTION; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; TREATMENT DURATION; ULCERATIVE COLITIS; URINALYSIS; VIRUS REACTIVATION; VIRUS SHEDDING;

ADOLESCENT; ADULT; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL AGENTS; BLOOD; CARRIER STATE; CHILD; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; JC VIRUS; MALE; POLYOMAVIRUS INFECTIONS; PREVALENCE; PROCTOCOLITIS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR VIRUS INFECTIONS; URINE; YOUNG ADULT;

EID: 84873970549     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23525     Document Type: Article

References (33)

1. Agostini HT, Ryschkewitsch CF, Stoner GL. 1996. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol 34:159-164.
2. Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Bonington A. 2003. BKV-DNA and JCV-DNA in CSF of patients with suspected meningitis or encephalitis. Infection 31:374-378.
3. Bellizzi A, Anzivino E, Ferrari F, Di Nardo G, Colosimo MT, Fioriti D, Mischitelli M, Chiarini F, Cucchiara S, Pietropaolo V. 2011. Polyomavirus JC reactivation and noncoding control region sequence analysis in pediatric Crohn's disease patients treated with infliximab. J Neurovirol 17:303-313.
4. Berger JR, Scott G, Albrecht J, Belman AL, Tornatore C, Major EO. 1992. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS 6:837-841.
5. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ. 2009. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067-1074.
6. Delbue S, Sotgiu G, Fumagalli D, Valli M, Borghi E, Mancuso R, Marchioni E, Maserati R, Ferrante P. 2005. A case of a progressive multifocal leukoencephalopathy patient with four different JC virus transcriptional control region rearrangements in cerebrospinal fluid, blood, serum, and urine. J Neurovirol 11:51-57.
7. Dubois V, Moret H, Lafon ME, Brodard V, Icart J, Ruffault A, Guist'hau O, Buffet-Janvresse C, Abbed K, Dussaix E, Ingrand D. 2001. JC virus genotypes in France: Molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis 183:213-217.
8. Elsner C, Dorries K. 1992. Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology 191:72-80.
9. Ferrante P, Mediati M, Caldarelli-Stefano R, Losciale L, Mancuso R, Cagni AE, Maserati R. 2001. Increased frequency of JC virus type 2 and of dual infection with JC virus type 1 and 2 in Italian progressive multifocal leukoencephalopathy patients. J Neurovirol 7:35-42.
10. Giannecchini S, Clausi V, Vultaggio A, Macera L, Maggi F, Martelli F, Azzi A, Maggi E, Matucci A. 2012. Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab. J Neurovirol. 18:55-61.
11. Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M, Johanns J, Lang Y, Markowitz J, Cohen S, Winter HS, Veereman-Wauters G, Ferry G, Baldassano R. 2011. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin 27:651-662.
12. Jensen PN, Major EO. 2001. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol 27:280-287.
13. Kangro HO, Osman HK, Lau YL, Heath RB, Yeung CY, Ng MH. 1994. Seroprevalence of antibodies to human herpesviruses in England and Hong Kong. J Med Virol 43:91-96.
14. Kean JM, Rao S, Wang M, Garcea RL. 2009. Seroepidemiology of human polyomaviruses. PLoS Pathogens 5:e1000363.
15. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 345:1098-1104.
16. Kumar D, Bouldin TW, Berger RG. 2010. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 62:3191-3195.
17. Kwok S, Higuchi R. 1989. Avoiding false positives with PCR. Nature 339:237-238.
18. Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, Crocellà L, Molinaro G, Rocca R, Cavallo R, Pera A. 2007. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 13:896-902.
19. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN. 2002. Life-threatening histoplasmosis complicating immunotherapy with tumour necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46:2565-2570.
20. Liptai Z, Papp E, Barsi P, Mihály I, Szalai E, Csomor J, Jelenik Z. 2007. Progressive multifocal leukoencephalopathy in an HIV-infected child. Neuropediatrics 38:32-35.
21. Lonergan R, Carr M, De Gascun C, Costelloe LF, Waters A, Coughlan S, Duggan M, Doyle K, Jordan S, Hutchinson MW, Hall WW, Tubridy NJ. 2009. Reactivation of BK polyomavirus in patients with multiple sclerosis receiving natalizumab therapy. J Neurovirol 15:351-359.
22. Losco A, Gianelli U, Cassani B, Baldini L, Conte D, Basilisco G. 2004. Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis 10:425-429.
23. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862-2869.
24. Pagani E, Delbue S, Mancuso R, Borghi E, Tarantini L, Ferrante P. 2003. Molecular analysis of JC virus genotypes circulating among the Italian healthy population. J Neurovirol 9:559-566.
25. Pineton de Chambrun G, Vernier-Massouille G, Colombel JF, Yazdanpanah Y. 2008. Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn's disease patients eligible for anti-alpha4 integrin therapy? Gut 57:1633-1634.
26. Rossi A, Delbue S, Mazziotti R, Valli M, Borghi E, Mancuso R, Calvo MG, Ferrante P. 2007. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol 79:408-412.
27. Rudick RA, O'Connor PW, Polman C, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, Goelz ES. 2010. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68:304-310.
28. Sadiq S, Puccio L, Brydon E. 2010. JCV detection in multiple sclerosis patients treated with natalizumab. J Neurol 257:954-958.
29. Sari I, Birlik M, Gonen C, Akar S, Gurel D, Onen F. 2008. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 14:2912-2914.
30. Tedesco M, Benevolo M, Frezza F, Mancini R, Carone MD, Mottolese M, Cosimelli M. 1999. Colorectal Kaposi's sarcoma in an HIV-negative male in association with ulcerative rectocolitis: A case report. Anticancer Res 19:3045-3048.
31. Torre-Cisneros J, Del Castillo M, Castón JJ, Castro MC, Pérez V, Collantes E. 2005. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 44:1132-1135.
32. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, Van Montfrans C, Hommes DW, Peppelenbosch MP, Van Deventer SJ. 2003. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124:1774-1785.
33. Verbeeck J, Van Assche G, Ryding J, Wollants E, Rans K, Vermeire S, Pourkarim MR, Noman M, Dillner J, Van Ranst M, Rutgeerts P. 2008. JC viral loads in patients with Crohn's disease treated with immunosuppression: Can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57:1393-1397.